# EDGAR Filing Document

**Accession Number:** 0002005369
**File Stem:** 0001193125-26-037644
**Filing Date:** 2026-2
**Character Count:** 25826
**Document Hash:** 60a4efdd26fd542a6ff2c31b380ad0f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-037644.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001193125-26-037644

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260202

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DEBBANE RAYMOND
- **CENTRAL INDEX KEY:** 0001053890

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598600

**MAIL ADDRESS:**
- **STREET 1:** C/O THE INVUS GROUP, LLC
- **STREET 2:** 750 LEXINGTON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Artal Group S.A.
- **CENTRAL INDEX KEY:** 0001053906

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** N4

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598596

**BUSINESS ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
- **BUSINESS PHONE:** (352) 22.42.59-1

**MAIL ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661

**FORMER NAME:**
- **FORMER CONFORMED NAME:** ARTAL GROUP S A
- **DATE OF NAME CHANGE:** 19980128
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Westend S.A.
- **CENTRAL INDEX KEY:** 0001283968

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598595

**BUSINESS ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
- **BUSINESS PHONE:** 3522242591

**MAIL ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661

**FORMER NAME:**
- **FORMER CONFORMED NAME:** WESTEND S.A.
- **DATE OF NAME CHANGE:** 20120816

**FORMER NAME:**
- **FORMER CONFORMED NAME:** WESTEND SA
- **DATE OF NAME CHANGE:** 20040317
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Artal International S.C.A.
- **CENTRAL INDEX KEY:** 0001218180

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598598

**BUSINESS ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
- **BUSINESS PHONE:** 352224259-1

**MAIL ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661

**FORMER NAME:**
- **FORMER CONFORMED NAME:** ARTAL INTERNATIONAL SCA
- **DATE OF NAME CHANGE:** 20110531

**FORMER NAME:**
- **FORMER CONFORMED NAME:** ARTAL INTERNATIONAL SA
- **DATE OF NAME CHANGE:** 20030210
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Artal Participations S.a r.l.
- **CENTRAL INDEX KEY:** 0002048403

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598599

**BUSINESS ADDRESS:**
- **STREET 1:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
- **BUSINESS PHONE:** 352224259-1

**MAIL ADDRESS:**
- **STREET 1:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stichting Administratiekantoor Westend
- **CENTRAL INDEX KEY:** 0001460840

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** XX

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598594

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** H.J.E. WENCKEBACHWEG 252
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1096 AS
- **BUSINESS PHONE:** 352-224-2591

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** H.J.E. WENCKEBACHWEG 252
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1096 AS
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Artal International Management S.A.
- **CENTRAL INDEX KEY:** 0001522131

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598597

**BUSINESS ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
- **BUSINESS PHONE:** 352224259-1

**MAIL ADDRESS:**
- **STREET 1:** VALLEY PARK
- **STREET 2:** 44, RUE DE LA VALLEE
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2661
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Siren, L.L.C.
- **CENTRAL INDEX KEY:** 0002005245

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598601

**BUSINESS ADDRESS:**
- **STREET 1:** 10 QUAIL ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06831
- **BUSINESS PHONE:** 212-371-1717

**MAIL ADDRESS:**
- **STREET 1:** THE INVUS GROUP, LLC
- **STREET 2:** 750 LEXINGTON AVENUE, 30TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Invus Global Management, LLC
- **CENTRAL INDEX KEY:** 0002005369

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 26598602

**BUSINESS ADDRESS:**
- **STREET 1:** THE INVUS GROUP, LLC
- **STREET 2:** 750 LEXINGTON AVENUE, 30TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-371-1717

**MAIL ADDRESS:**
- **STREET 1:** THE INVUS GROUP, LLC
- **STREET 2:** 750 LEXINGTON AVENUE, 30TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEXICON PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001062822
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 760474169
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2445 TECHNOLOGY FOREST BLVD.
- **STREET 2:** SUITE 1100
- **CITY:** THE WOODLANDS
- **STATE:** TX
- **ZIP:** 77381
- **BUSINESS PHONE:** 2818633000

**MAIL ADDRESS:**
- **STREET 1:** 2445 TECHNOLOGY FOREST BLVD.
- **STREET 2:** SUITE 1100
- **CITY:** THE WOODLANDS
- **STATE:** TX
- **ZIP:** 77381

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXICON PHARMACEUTICALS, INC./DE
- **DATE OF NAME CHANGE:** 20070426

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXICON GENETICS INC/TX
- **DATE OF NAME CHANGE:** 20000126

## Exhibit 99.1

**Exhibit 99.1**

SIGNATURE PAGE

---

| |
|:---|
| INVUS PUBLIC EQUITIES, L.P.<br>Signature <u>/s/ Raymond Debbane</u><br>Name/Title: Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner<br>Date: February 4, 2026 |
| <br>INVUS PUBLIC EQUITIES ADVISORS, LLC <br>Signature <u>/s/ Raymond Debbane</u><br>Name/Title: Raymond Debbane, President<br>Date: February 4, 2026 |
| <br>INVUS GLOBAL MANAGEMENT, LLC <br>Signature <u>/s/ Raymond Debbane</u><br>Name/Title: Raymond Debbane, President<br>Date: February 4, 2026 |
| <br>SIREN, L.L.C.<br>Signature <u>/s/ Raymond Debbane</u><br>Name/Title: Raymond Debbane, President<br>Date: February 4, 2026 |
| <br>ULYS, L.L.C.<br>Signature <u>/s/ Raymond Debbane</u> <br>Name/Title: Raymond Debbane, President<br>Date: February 4, 2026<br>|

---

------

<br>RAYMOND DEBBANE<br>Signature <u>/s/ Raymond Debbane</u><br>Name/Title: Raymond Debbane<br>Date: February 4, 2026<br>

---

| |
|:---|
| ARTAL PARTICIPATIONS S.à r.l.<br>Signature: <u>/s/ Pierre Claudel</u><br>Name/Title: Pierre Claudel, Manager<br>Date: February 4, 2026 |
| <br>ARTAL INTERNATIONAL S.C.A.<br>Signature: <u>/s/ Anne Goffard</u><br>Name/Title: Anne Goffard, Managing Director of Artal International Management S.A., its managing partner<br>Date: February 4, 2026 |

---

---

| |
|:---|
| ARTAL INTERNATIONAL MANAGEMENT S.A. <br>Signature: <u>/s/ Anne Goffard</u><br>Name/Title: Anne Goffard, Managing Director<br>Date: February 4, 2026 |
| <br>ARTAL GROUP S.A.<br>Signature: <u>/s/ Anne Goffard</u><br>Name/Title: Anne Goffard, Authorized Person<br>Date: February 4, 2026 |
| <br>WESTEND S.A.<br>Signature: <u>/s/ Anne Goffard</u><br>Name/Title: Anne Goffard, Managing Director<br>Date: February 4, 2026 |

---

------

---

| |
|:---|
| <br>STICHTING ADMINISTRATIEKANTOOR WESTEND<br>Signature: <u>/s/ Amaury Wittouck</u><br>Name: Amaury Wittouck, Sole Member of the Board<br>Date: February 4, 2026 |
| <br>AMAURY WITTOUCK <br>Signature: <u>/s/ Amaury Wittouck</u><br>Name: Amaury Wittouck<br>Date: February 4, 2026 |

---

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Invus Global Management, LLC<br><sub>(Last) (First) (Middle)</sub><br>750 LEXINGTON AVENUE, 30TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Siren, L.L.C.<br><sub>(Last) (First) (Middle)</sub><br>C/O THE INVUS GROUP, LLC<br>750 LEXINGTON AVENUE 30TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DEBBANE RAYMOND<br><sub>(Last) (First) (Middle)</sub><br>C/O THE INVUS GROUP, LLC<br>750 LEXINGTON AVENUE 30TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Artal Participations S.a r.l.<br><sub>(Last) (First) (Middle)</sub><br>VALLEY PARK 44, RUE DE LA VALLEE<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2661<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Artal International S.C.A.<br><sub>(Last) (First) (Middle)</sub><br>VALLEY PARK, 44, RUE DE LA VALLEE<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2661<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Artal International Management S.A.<br><sub>(Last) (First) (Middle)</sub><br>VALLEY PARK, 44, RUE DE LA VALLEE<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2661<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Artal Group S.A.<br><sub>(Last) (First) (Middle)</sub><br>VALLEY PARK, 44, RUE DE LA VALLEE<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2661<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Westend S.A.<br><sub>(Last) (First) (Middle)</sub><br>VALLEY PARK, 44, RUE DE LA VALLEE<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2661<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stichting Administratiekantoor Westend<br><sub>(Last) (First) (Middle)</sub><br>H.J.E. WENCKEBACHWEG 252<br><sub>(Street)</sub><br>AMSTERDAM, P7 1096 AS<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-02 |  | A<sup>(1)</sup> |  | 18553846 | A | $1.30 | 154734327 | I | See Footnotes<sup>(4)(9)(15)</sup> |
| Common Stock | 2026-02-02 |  | A<sup>(1)</sup> |  | 3846154 | A | $1.30 | 7362368 | I | See Footnotes<sup>(5)(10)(15)</sup> |
| Common Stock | 2026-02-02 |  | P<sup>(2)</sup> |  | 1538462 | A | $1.30 | 1538462 | I | See Footnotes<sup>(6)(11)(15)</sup> |
| Series B Convertible Preferred Stock | 2026-02-02 |  | A<sup>(3)</sup> |  | 367145.12 | A | $65.00 | 367145.12 | I | See Footnotes<sup>(4)(9)(15)</sup> |
| Common Stock |  |  |  |  |  |  |  | 35402689 | I | See Footnotes<sup>(7)(12)(15)</sup> |
| Common Stock |  |  |  |  |  |  |  | 5451204 | I | See Footnotes<sup>(8)(13)(15)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1385689 | I | See Footnotes<sup>(14)(15)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026.

(2) On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering.

(3) On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the "Preferred Purchase Agreement") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026.

(4) These securities are directly held by Artal Participations S.a r.l.

(5) These securities are directly held by Invus Public Equities, L.P.

(6) These securities are directly held by Avicenna Life Sci Master Fund LP

(7) These securities are directly held by Invus, L.P.

(8) These securities are directly held by Invus US Partners LLC

(9) The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

(10) The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.

(11) The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

(12) The general partner of Invus, L.P. is Invus Advisors, L.L.C. The managing member of Invus Advisors, L.L.C. is Invus Global Management, LLC. The managing member of Invus Global Management, LLC. is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.

(13) The managing member of Invus US Partners LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

(14) These securities are directly held by Mr. Raymond Debbane.

(15) Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

**Remarks:**
For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.

**Signature:** See Exhibit 99.1  
**Date:** 2026-02-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**